Diabetes mellitus (DM) has a bidirectional association with pancreatic cancer (PaC); however, its effect on clinical outcomes has not been thoroughly evaluated. We analyzed these data in a large sample of PaC subjects who had undergone surgical resection.
INTRODUCTION
Pancreatic cancer (PaC) is the fourth most common cause of cancer death in the United States ( 1 ) . Th e 5-year survival rate remains a dismal 5 % , refl ecting the large proportion of patients with locally advanced or metastatic disease at initial presentation and poor treatment options. Progress in cancer screening and treatment options has been slow for multiple reasons. Further understanding of the complex relationship between PaC and diabetes mellitus (DM) may permit advancements in these areas.
One unique clinical fi nding in subjects with PaC is a common association with DM. Although DM has been reported as a risk factor for other cancers, there is a disproportionately higher number of PaC patients with DM compared with other cancers ( 2 ) . For PaC, long-standing DM has been identifi ed as a risk factor in recent meta-analyses ( 3 -5 ) . In addition, the risk for PaC is increasingly higher when the DM is new-onset (i.e., DM onset occurs within 36 months of cancer diagnosis) ( 6 ) . New-onset DM represents almost 75 % of DM that is associated with PaC ( 7 ) . Although the DM can develop as the result of the tumor mass itself, it oft en occurs before the appearance of a radiographically visible mass, suggesting the potential role for a tumor-secreted humoral mediator of DM. Th e peculiarities of this relationship suggest that DM
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Cancer: A Retrospective, Cohort Study has an important role in the early stages of PaC, either as a tumor growth-promoting factor or tumor by-product, and thus additional understanding has potential implications for both screening and potential treatment ( 6 ) .
Studies investigating the eff ect of DM on clinical outcomes in PaC are challenging to execute owing to the relative rarity of the disease and the need to control for a wide range of clinical variables. Th e ideal study population for examining this association comprises subjects who undergo surgical resection because this provides complete pathologic staging (e.g., accurate tumor size, extension to surrounding tissues, lymph node status, and grade), which is oft en not obtained for subjects with apparently metastatic disease at diagnosis. Recently, Chu et al. ( 8 ) examined over 200 patients who were treated with a " surgery fi rst " approach and found that diabetic subjects had a larger tumor size and reduced postoperative survival. Interestingly, the eff ect sizes were larger in subjects with new-onset DM compared with long-standing DM.
Our institution has also practiced a " surgery fi rst " approach whereby patients with an anatomically resectable cancer are off ered surgery without neoadjuvant treatment (i.e., chemotherapy and / or radiation). Th us, in general, there is no confounding from the potential treatment eff ects of neoadjuvant therapy. It is important to confi rm the previous observations and further understand the potential interaction between PaC and DM to increase our understanding of tumorigenesis and potentially identify a new pathway for targeted therapies. We examined a large cohort of PaC (ductal adenocarcinoma) patients who had undergone surgical resection to determine whether DM status is associated with poorer clinical outcomes, including tumor size, stage of disease at the time of surgery, and postoperative survival.
METHODS
Th is study protocol was approved by the Mayo Clinic Institutional Review Board, and informed consent was obtained from all subjects.
Patient recruitment and data collection
PaC patients (ductal adenocarcinoma) were rapidly and systematically identifi ed and approached, using methodology reported previously at Mayo Clinic Rochester, Mayo Clinic Arizona, and Mayo Clinic Florida between 1 January 2000 and 31 December 2010 ( 9 ) . A total of 1,490 enrolled patients completed the risk factor questionnaire ( Figure 1 ). Subjects were also included if the questionnaire was completed aft er the date of surgery when the preoperative DM status could be confi rmed. Th e questionnaire included medical and diabetes history, health habits, family history, and performance status.
Fasting blood glucose (FBG) levels were obtained from the electronic medical record for most subjects at study entry. DM was defi ned as those patients with an FBG level > 126 mg / dl or, for those without FBGs, a self-report of DM on the risk factor questionnaire ( Figure 1 ). In those with a self-report of DM, the status was confi rmed initially by manual review of medical records to identify those receiving antidiabetic treatment preoperatively, and then by review of preoperative FBG status. New-onset DM was defi ned as the onset of DM up to 36 months before PaC diagnosis and long-standing DM if the duration was longer ( 10 ).
PaC w/ completed questionnaire, n =1,490
Excluded: no surgery n =781 Excluded: Palliative or aborted surgery, n =178 Neoadjuvant chemo, n =43 
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Additional data regarding preoperative laboratory data and intraoperative and tumor data are prospectively collected and archived by an oncologist with an expertise in gastrointestinal cancers (PAB). Intraoperative and tumor-related fi ndings were independently reviewed by a second clinician (PAH), and any discrepancies were resolved. Cancer staging was recorded according to AJCC 7th edition staging criteria. Vital status of subjects was collected using multiple sources as part of routine research follow-up; sources included periodic mailings, medical records, tumor registry, and death indices from online services.
Th e study group of interest comprised those who were undergoing surgical resection with the intent to completely remove the cancer (i.e., a potentially " curative " surgery). Subjects with inoperable cancer were not included. Operative reports were reviewed if any surgery was performed to exclude subjects who had either a palliative or aborted (owing to the presence of distant disease) procedure. In some instances, surgery was performed elsewhere, and thus some operative details and tumor data were unavailable. Finally, 43 patients (6.1 % of potentially eligible subjects undergoing surgery) who received neoadjuvant treatment (i.e., chemotherapy with or without radiation) were not included to minimize confounding from previous treatment eff ects on the tumor or glycemic status.
Statistical analyses
Th e date of cancer diagnosis was defi ned as the date of tissue diagnosis or surgical resection, whichever came fi rst. Date of death or last known date alive was selected from the most current data among the multiple sources described above. Survival (the primary end point) was determined from the date of cancer diagnosis to the date of death or last known alive date. Th ree subgroups were identifi ed at the time of study conception for comparison according to (i) the duration of DM before cancer diagnosis (new-onset vs. long-standing DM), (ii) DM treatment status (previous DM treatment vs. no DM treatment), and (iii) proximity to study center (limited to those residing within a 125-mile radius of Rochester, MN, at study enrollment).
Clinical characteristics and operative fi ndings were compared between DM and non-DM patients using Pearson ' s χ 2 -tests for categorical variables and Kruskal -Wallis tests for continuous variables. Kaplan -Meier curves with estimated median survival (logrank test for statistical signifi cance) were used to explore survival. Cox proportional hazards regression analysis was used to further investigate the relationship between DM status and survival; multivariable models were considered to adjust for other clinically relevant covariates. Th ese covariates were defi ned a priori as follows: age at PaC diagnosis, gender, body mass index (BMI), weight loss percentage, smoking status, family history of DM, DM status, DM treatment, maximum tumor size, tumor grade, number of positive lymph nodes, margin status, adjuvant chemotherapy, and stage at PaC diagnosis.
Tumor size was investigated as a secondary end point using multivariable regression modeling (test for signifi cance from likelihood ratio tests). Clinically relevant covariates for this analysis were also defi ned a priori as follows: age at PaC diagnosis, gender, BMI, family history of DM, duration of DM, site of pancreatic mass, stage at diagnosis, tumor grade, number of positive nodes, angiolymphatic invasion, and perineural invasion. Statistical signifi cance was P < 0.05. All analyses were performed using the SAS soft ware, version 9.1.3 (SAS Institute, Cary, NC).
RESULTS

Study population characteristics
Surgical intervention was undertaken for 709 / 1,490 (47.6 % ) eligible participants, which refl ects the referral bias of our center. Th ose who underwent surgery as a palliative bypass or had an aborted procedure owing to locally unresectable or metastatic disease ( n = 178) or who received neoadjuvant chemotherapy ( n = 43) were excluded from the analyses.
In 488 subjects undergoing surgical resection with curative intent, 382 (78.3 % ) had a pancreaticoduodenectomy, 84 (17.2 % ) had a distal pancreatectomy, and 22 (4.5 % ) had a total pancreatectomy. Portal or superior mesenteric vein reconstruction was performed for 73 (17 % ) subjects (data unavailable for 57 subjects). Complete gross resection (R0 -R1) was achieved in 463 / 470 (99 % ) patients. Tumor characteristics for patients undergoing surgery with curative intent are shown in Table 1 .
Comparison based on DM status
DM status was determined for all patients as depicted in Figure 1 . A total of 275 (56 % ) subjects with PaC had DM. Th e DM diagnosis was made on the basis of an elevated FBG for 138 subjects who were otherwise unaware of a history of DM. Th e clinical profi les of diabetic and nondiabetic patients were compared ( Table 2 ). Th ose with DM had signifi cantly higher usual adult BMI and were more likely to have a family history of DM, but the two groups otherwise had similar clinical profi les. Th ere were no diff erences between the preoperative laboratory data including hemoglobin, leukocytes, absolute neutrophil count, carbohydrate antigen 19 -9, albumin, asparatate aminotransferase, alanine transaminase, total / direct bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, and prothrombin time levels. Operative fi ndings are compared in Table 3 . Diabetic subjects had larger tumor sizes than nondiabetic subjects, but the distribution of AJCC stage at diagnosis was similar. Generally, subjects with DM were more likely to have a tumor with an advanced histologic grade (i.e., poorly or undiff erentiated).
Comparisons in the population-based subgroup
Our clinical practice is predominantly referral-based. To evaluate referral bias, particularly in regard to cancer stage, univariable comparisons were repeated between diabetic and nondiabetic groups for subjects ( n = 151) living within 125 miles of Rochester, MN ( Table 4 ). Diabetic subjects remained more likely to have a higher adult BMI, family history of DM, and have a pancreaticoduodenectomy. In addition, there was a greater proportion of weight loss and higher median carbohydrate antigen 19 -9 levels in diabetics at the time of cancer diagnosis. Tumor size and
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Pancreatic Cancer-Associated Diabetes Mellitus histologic tumor grade were no longer statistically signifi cant, but the direction of eff ect was the same as that in the total study population. Th e AJCC stage at diagnosis was similar between those with and without DM for this nonreferral-based subgroup.
Comparisons based on the duration of DM
To determine whether the duration of DM infl uenced the clinical outcomes, 204 DM patients were further evaluated on the basis of the duration of DM (duration of DM could not be determined for 71 subjects). DM was of new onset for the majority of diabetic subjects (164, 80 % ). Th e clinical characteristics presented in Table 2 were compared between those with new-onset DM and long-standing DM. Usual adult BMI was higher in those with longstanding DM compared with new-onset DM (30.8 vs. 28.5 kg / m 2 , respectively, P = 0.012). In addition, subjects with new-onset DM were less likely to be smokers (60.4 vs. 80.0 % , P = 0.020 or to have a family history of DM (56.1 vs. 82.5 % , P = 0.002). Th e groups were similar in regard to preoperative laboratory and operative fi ndings with the exception of mean tumor size (cm), which was larger in new-onset DM (3.7 vs. 3.2, P = 0.022). Findings in the new-onset DM group were similar when compared with nondiabetic subjects, but the diff erence in family history of DM was no longer present.
Comparisons based on DM treatment
DM subjects were also compared on the basis of the use of antidiabetic medications. A total of 88 DM subjects were using either an oral medication or insulin at the time of cancer diagnosis. Th ose receiving treatment had a higher mean adult BMI (30.0 kg / m 2 (s.d. 5.3) vs. 28.5 kg / m 2 (5.9), P = 0.014) and a higher proportion of family history for DM (69.3 vs. 51.9 % , P = 0.006).
Tumor size
Several factors were signifi cantly associated with increased tumor size in addition to DM on univariable analysis, including increasing usual adult BMI ( P = 0.033), site of mass (body / tail vs. head) ( P < 0.001), advanced tumor grade (i.e., poorly diff erentiated or undiff erentiated) ( P < 0.001), > 3 positive lymph nodes ( P = 0.023), positive family history of DM ( P = 0.004), and recent onset of DM (vs. long-standing) ( P = 0.025). Multivariable analysis controlling for these variables and others with P < 0.20 on univariable analysis demonstrated an independent relationship between tumor size and age, adult BMI, site of mass, stage at diagnosis, tumor grade, and duration of DM ( Table 5 ).
Survival analysis
Th e postoperative median survival for all subjects undergoing cancer resection with curative intent was 24.4 months. Median survival was similar in those with and without DM (23.7 vs. 26.4 months, respectively, P = 0.610; Figure 2 ). On multivariable survival analysis, the presence of DM was not associated with an increased risk for death (hazard ratio 1.06, 95 % confi dence interval 0.81 -1.38, P = 0.676). Although the median survival tended to be shorter in those with new-onset compared with long-standing DM, the diff erence was not statistically diff erent (23.5 vs. 27.1 months, respectively, P = 0.715; Figure 3 ). In the DM group, median survival was not infl uenced by preoperative diabetic treatment status (23.5 months for treated vs. 23.8 months for untreated, P = 0.743). Specifi cally, the median postoperative survival in those who used metformin (27.1 months) or insulin (25.3 months) was similar to that of diabetics not on treatment (23.8 months, P = 0.367 and 0.912, for the respective comparisons).
DISCUSSION
In this cohort study of PaC subjects who had undergone surgical resection, we demonstrated that, although subjects with DM have a greater tumor size, this is not associated with worse survival aft er cancer resection. Despite the larger tumor size, DM and non-DM subjects have a similar cancer stage at the time of surgery. Th e tumor size is independently associated with preoperative DM and is more prominent in diabetics with new-onset compared with long-standing DM. Th e duration of DM (new-onset vs. longstanding) and the use of antidiabetic medications before diagnosis did not aff ect the postoperative survival. In brief, preoperative DM status does not infl uence clinical outcomes, with the exception of tumor size, in those undergoing surgical resection for PaC.
Previous large epidemiologic studies have repeatedly shown that those with DM are more likely to develop and die from PaC compared with subjects without DM. Th ese predominantly databasederived analyses lacked the necessary information to control for important confounders, including age at diagnosis, tumor grade, and cancer stage. A previous, well-designed case -control study evaluating 209 subjects who had undergone surgical resection All values are presented as n ( % of available data) unless otherwise indicated.
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or nodal involvement). In summary, when important confounders were considered in the analysis of our large cohort (nearly 500 subjects), we were unable to confi rm the previous observation that preoperative DM negatively infl uences postoperative survival. Th e marked eff ect on survival of early metastases and lymphatic spread in PaC cannot be overlooked. As a consequence of the large eff ect of cancer stage on survival, the potential infl uence of a single comorbidity or disease modifi er must have a large eff ect to be clinically apparent. Th erefore, even if DM aff ects prognosis, this eff ect is likely overshadowed by the powerful infl uence of early metastases. Nonetheless, the increased tumor size may still be mechanistically relevant. As tumors are three-dimensional objects, an increase in provided results from a single-center study ( 10 ) . Th e investigators noted a similar increase in tumor size in subjects with DM compared with those without DM (3.8 vs. 3.2 cm, P < 0.01). Th ey found that the postoperative median survival was reduced in DM subjects compared with non-DM subjects (15 vs. 17 months, P = 0.02). Although the absolute decrease in median survival for DM subjects in our study was similar, the increased overall median survival in our series (24 months) compared with their series (16 months) may partially explain our inability to conclude a statistically signifi cant diff erence. However, their multivariable survival analysis did not account for age and margin status (the subjects in our study were younger and less likely to have positive margins ). By this measure, the observed increase in tumor size between DM and non-DM subjects, although < 5 mm in diameter, results in an approximate 30 % increase in tumor volume.
As it remains unclear whether DM incites tumor growth and / or is a consequence of tumor growth (likely via humoral mechanisms), the true importance of the increased size is not fully realized at this time. An alternative explanation is that the negative impact on control before, at the time of diagnosis, and aft er diagnosis may provide further insights. Th ere is increasing attention to the potential for antidiabetic medications to alter the risk of developing PaC; however, results have been mixed ( 11 ) . A recent meta-analysis demonstrated an increased risk for developing PaC in subjects on sulfonylureas, but there was no signifi cant association with metformin, thiazolidinediones, and insulin ( 12 ) . In our subgroup analysis of diabetic subjects who received the various antidiabetic medications (e.g., metformin, insulin, and others) before cancer diagnosis, we were unable to demonstrate a signifi cant diff erence in postoperative survival compared with diabetics who did not receive these treatments. Th is was a retrospective cohort study of patients who had completed an extensive risk factor questionnaire. Availability of extensive historical and preoperative and postoperative clinical details allowed us to simultaneously assess a large number of potential confounding variables within the same study population. Th e high survival by the diabetic state is neutralized by cancer resection. In a previous study, cancer resection has been shown to ameliorate the hyperglycemic changes of PaC-associated DM ( 7 ). Th is eff ect was even more apparent in those with new-onset DM, in which the DM resolved in more than half of the patients following surgical resection. According to this hypothesis, neutralization of the diabetic state by surgical resection could potentially mitigate any potential infl uence of DM, making postoperative survival comparable to those who were not diabetic preoperatively.
It has not been directly demonstrated that systemic lowering of serum glucose (i.e., by providing antidiabetic treatments) in subjects with PaC infl uences clinical outcomes or even decreases the amount of glucose available in the tumor microenvironment. In our study, data regarding hemoglobin A1c values were not consistently available for enough subjects to make any meaningful comparison in this regard. Future studies presenting data on the degree of glycemic 
Pancreatic Cancer-Associated Diabetes Mellitus availability of preoperative FBG values also allowed us to identify many subjects with new-onset DM. Unfortunately, many subjects with self-reported absence of DM did not have an available preoperative blood glucose collected in the fasting state. A sensitivity analysis was conducted (data not shown) excluding these subjects, and the results remained unchanged. Th e current study is the largest evaluation of DM status in subjects who underwent surgical resection of PaC. Th is is a refl ection of the existing high-volume, referral-based medical and surgical Pancreas clinic and incorporation of the three Mayo Clinic practice sites. To ensure that the fi ndings were not altered by the referral nature of our practice, we performed subgroup analyses for subjects living in proximity to the primary study site; similar results for tumor size, cancer stage at diagnosis, and postoperative survival were seen.
In conclusion, although the presence of DM at the time of PaC diagnosis is associated with increased tumor size, there is no negative impact on the cancer stage at the time of surgery or survival following cancer resection. Even though the absolute diff erence in tumor size is relatively small (approximately 3 mm), it refl ects a noteworthy increase in relative tumor volume. If DM negatively aff ects these outcomes, the eff ect is either mitigated by tumor resection or simply overshadowed by the profound infl uence of early metastases. Further studies exploring the infl uence of DM on tumor size may help understand factors involved in tumor growth but may not yield meaningful treatment options.
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